What is Vericel's market cap?

Vericel (VCEL) has a market capitalization of $2.3B and trades on NASDAQ.

What is Vericel's revenue and profitability?

Vericel generated $292.1M in trailing twelve-month revenue with net income of $21.5M, representing a net margin of 7.3%. Gross margin stands at 74.8%, with free cash flow of $47.5M. These figures are based on the Q1 2026 filing.

Who are Vericel's competitors?

Vericel's key competitors include Zimmer Biomet Holdings, Inc., ConMed Corporation, Stryker Corporation, and others. These companies compete in similar markets and product categories.

Who does Vericel partner with?

Vericel's notable partners include MediWound Ltd., Matricel GmbH, Orsini Pharmaceutical Services, Inc., and others.

Where is Vericel headquartered?

Vericel is headquartered in United States of America and employs approximately 314 people. It has been publicly traded since 1997.

Vericel

VCEL

Vericel Corporation is a commercial-stage biopharmaceutical company specializing in advanced therapies for the sports medicine and severe burn care markets.

Market cap

$2.31B+13.1%

Revenue$292.1M+22.5%

Net income$21.5M+621%

Free cash flow$47.5M+322%

EPS (diluted)$0.42+950%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$68.4MBeat by $4.7M EPS-$0.12Beat by $0.03

Read the full report

Next report

Jul 30, 2026 (Tomorrow)

Revenue estimate$72.7M

EPS estimate-$0.04

Financials

Q1 2026

Income statement

See full

Revenue$68.4M+30.1%

Gross profit$49.3M+35.8%

Operating income-$8.1M+37.0%

Net income-$6.3M+44.0%

EPS (diluted)-$0.12+47.8%

Balance sheet

See full

Cash & equivalents$109.3M+37.1%

Total debt$95.0M-4.6%

Total equity$356.2M+20.6%

Total assets$485.6M+14.4%

Cash flow

See full

Operating cash flow$16.4M+148%

CapEx$1.3M-91.2%

Free cash flow$15.1M+299%

Valuation & ratios

Valuation

See full

Market cap$2.31B+13.1%

Enterprise value$2.3B+9.2%

P/E107.8×-186×

P/S7.9×-0.5×

Profitability

See full

Gross margin74.8%+2.3pp

Operating margin5.4%+4.6pp

Net margin7.3%+6.1pp

FCF margin16.3%—

Returns & leverage

See full

Return on equity6.6%+5.5pp

Debt / equity0.3×-0.1×

Current ratio5.2×+0.2×

Segments

By product

See full

M A C I Implants and kits$56.4M+21.8%

MACI implants, kits, and instruments$41.5M+30.4%

Epicel$10.9M+119%

Biopsy kits$606.0K+1.7%

Competitors

By market cap

Stryker$129.09B-15.7%

Zimmer Biomet Holdings$17.8B-6.2%

Vericel$2.3B+10.9%

LeMaitre Vascular$2.3B+21.3%

CONMED$1.3B-15.4%

Organogenesis Holdings Inc.$328.1M-48.5%

Anika Therapeutics$199.9M+23.0%

Celularity$21.7M-72.4%

By revenue growth

Anika Therapeutics+29.5%

Vericel+22.5%

LeMaitre Vascular+13.3%

Organogenesis Holdings Inc.+12.2%

Zimmer Biomet Holdings+9.2%

Stryker+8.8%

CONMED+4.1%

By net margin

LeMaitre Vascular24.35%+4.4pp

Stryker13.21%+0.9pp

Zimmer Biomet Holdings9.05%-2.8pp

Vericel7.35%+6.1pp

CONMED4.0%-5.0pp

Organogenesis Holdings Inc.0.528%+4.0pp

Anika Therapeutics-3.38%+61.7pp

Profile

Vericel Corporation is a commercial-stage biopharmaceutical company specializing in advanced therapies for the sports medicine and severe burn care markets. The company develops and commercializes autologous cell therapies and specialty biologics designed to regenerate skin and knee cartilage. Its core value proposition lies in its proprietary tissue engineering technologies that utilize a patient's own cells to provide durable, long-term healing solutions.

Competitive position

Vericel holds a leading position as the provider of the only FDA-approved autologous cultured chondrocyte implant (MACI) and the only FDA-approved cultured epidermal autograft for large burns (Epicel).

GeographiesUnited States, North America, United Kingdom

Customer segmentsSpecialized Healthcare Providers, Surgical Centers, Government/Military Healthcare

Business modelSpecialty Biologics Manufacturing, Direct-to-Hospital Sales, Licensing and Distribution

SuppliersPorcine-derived collagen membrane suppliers, Specialty chemical and enzyme manufacturers, Biopsy tissue collection services, Raw material suppliers for bromelain

CustomersSpecialty pharmacies, Hospitals and burn centers, Military medical facilities, Specialty distributors

CountryUnited States of America

Listed1997

Employees314.0

CEODominick C. Colangelo

SectorHealthcare

IndustryBiotechnology

Websitevcel.com

FilingsSEC EDGAR

Ask your AI about Vericel.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vericel's market cap?: Vericel (VCEL) has a market capitalization of $2.3B and trades on NASDAQ.
What is Vericel's revenue and profitability?: Vericel generated $292.1M in trailing twelve-month revenue with net income of $21.5M, representing a net margin of 7.3%. Gross margin stands at 74.8%, with free cash flow of $47.5M. These figures are based on the Q1 2026 filing.
Who are Vericel's competitors?: Vericel's key competitors include Zimmer Biomet Holdings, Inc., ConMed Corporation, Stryker Corporation, and others. These companies compete in similar markets and product categories.
Who does Vericel partner with?: Vericel's notable partners include MediWound Ltd., Matricel GmbH, Orsini Pharmaceutical Services, Inc., and others.
Where is Vericel headquartered?: Vericel is headquartered in United States of America and employs approximately 314 people. It has been publicly traded since 1997.